JP2006514636A - 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 - Google Patents

抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 Download PDF

Info

Publication number
JP2006514636A
JP2006514636A JP2004557434A JP2004557434A JP2006514636A JP 2006514636 A JP2006514636 A JP 2006514636A JP 2004557434 A JP2004557434 A JP 2004557434A JP 2004557434 A JP2004557434 A JP 2004557434A JP 2006514636 A JP2006514636 A JP 2006514636A
Authority
JP
Japan
Prior art keywords
wta
infection
aureus
antibody
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004557434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514636A5 (cg-RX-API-DMAC7.html
Inventor
コカイ−クン，ジョン・フィッツジェラルド
クリスティアン，サッシャ・エイ
ヴァイデンマイアー，クリストファー
ペスヒェル，アンドレアス
Original Assignee
バイオシネクサス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオシネクサス インコーポレーテッド filed Critical バイオシネクサス インコーポレーテッド
Publication of JP2006514636A publication Critical patent/JP2006514636A/ja
Publication of JP2006514636A5 publication Critical patent/JP2006514636A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2004557434A 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸 Pending JP2006514636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43022502P 2002-12-02 2002-12-02
PCT/US2003/038132 WO2004050846A2 (en) 2002-12-02 2003-12-01 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines

Publications (2)

Publication Number Publication Date
JP2006514636A true JP2006514636A (ja) 2006-05-11
JP2006514636A5 JP2006514636A5 (cg-RX-API-DMAC7.html) 2007-06-07

Family

ID=32469426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004557434A Pending JP2006514636A (ja) 2002-12-02 2003-12-01 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸

Country Status (6)

Country Link
US (1) US20040247605A1 (cg-RX-API-DMAC7.html)
EP (1) EP1567868A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006514636A (cg-RX-API-DMAC7.html)
AU (2) AU2003298770A1 (cg-RX-API-DMAC7.html)
CA (1) CA2507711A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004050846A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014237687A (ja) * 2007-08-31 2014-12-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
JP2016525343A (ja) * 2013-05-31 2016-08-25 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2016532433A (ja) * 2013-05-31 2016-10-20 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2019519509A (ja) * 2016-05-18 2019-07-11 ゲンマブ ビー．ブイ． 感染性疾患の治療における抗体およびその使用方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US8394379B2 (en) 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
WO2007024852A2 (en) * 2005-08-22 2007-03-01 Biosynexus Incorporated Methods for testing vaccine candidates against bacterial infection in rodents
AU2006303998A1 (en) * 2005-10-11 2007-04-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Targeted biocides
US20110044968A1 (en) * 2008-03-10 2011-02-24 Pharmal N Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US8598342B2 (en) 2008-06-12 2013-12-03 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
KR20110124060A (ko) * 2010-05-10 2011-11-16 부산대학교 산학협력단 Ｗｔａ를 유효성분으로 함유하는 백신 조성물
EP2780351B1 (en) 2011-11-18 2019-12-18 National Research Council of Canada (NRC) Clostridium difficile lipoteichoic acid and uses thereof
CN103383354B (zh) * 2012-05-03 2016-11-09 北京博迈世纪生物技术有限公司 一种检测肠毒素sea的磁微粒化学发光试剂盒的检测方法
EP2848257A4 (en) * 2012-05-07 2015-12-02 Mogam Biotechnology Inst VACCINE COMPOSITION FOR PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
AR096388A1 (es) * 2013-05-31 2015-12-30 Genentech Inc Anticuerpos anti-ácido teicoico de pared y sus conjugados
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
CN106413737A (zh) * 2014-05-29 2017-02-15 株式会社绿十字 用于预防或治疗金黄色葡萄球菌感染的组合物
BR112017011325A2 (pt) * 2014-12-03 2020-07-21 Genentech, Inc. ?composto de conjugado anticorpo?antibiótico, composição, método de tratamento de uma infecção, método para matar staph aureus, processo para produzir o conjugado, kit para o tratamento de uma infecção, intermediários antibiótico-ligante e ligante-droga?
WO2017010845A1 (ko) * 2015-07-15 2017-01-19 재단법인 목암생명과학연구소 포도상구균 감염 질환의 예방 또는 치료용 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250262A (en) * 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
US5139933A (en) * 1989-09-26 1992-08-18 Vicam, L.P. Assay method for detecting listeria
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5290707A (en) * 1991-11-25 1994-03-01 The United States Of America As Represented By The Secretary Of The Army Method for detection of microorganisms
US5367058A (en) * 1993-08-25 1994-11-22 Becton, Dickinson And Company Modified antibodies with increased affinity
EP0732936B1 (de) * 1993-12-09 2000-03-29 Heinrich Exner Adjuvans für antigene, verfahren zur herstellung und verwendung
US6350597B1 (en) * 1994-01-13 2002-02-26 E. I. Du Pont De Nemours & Company Riboflavin synthase genes and enzymes and methods of use
US6203997B1 (en) * 1994-06-08 2001-03-20 Sepsis, Inc. Quantitation of analytes in whole blood
ES2178699T3 (es) * 1995-01-30 2003-01-01 Lunamed Ag Preparaciones antitumorales que contienen un acido lipoteicoico procedente de streptococcus.
EP0861321B1 (en) * 1995-10-13 2006-05-31 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5889171A (en) * 1997-07-18 1999-03-30 Smithkline Beecham Corporation TarF
ATE316794T1 (de) * 1997-07-23 2006-02-15 Ambi Inc Pharmazeutische zusammensetzungen enthaltend lysostaphin allein oder in kombination mit einem antibiotikum zur behandlung von staphylokokkeninfektionen
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) * 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
KR100790653B1 (ko) * 1998-12-22 2007-12-31 마이크로싸이언스 리미티드 유전자와 단백질들, 및 그들의 사용
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
CA2369762A1 (en) * 1999-04-16 2000-10-26 Peter P. Lee A method for improving the half-life of soluble viral-specific ligands on mucosal membranes
US6974700B2 (en) * 1999-06-14 2005-12-13 Martin Levine Kit for use in predicting refractory periodontal disease
WO2002045742A2 (en) * 2000-09-12 2002-06-13 U.S. Army Medical Research And Materiel Command Lipoteichoic acid immunogenic compositions and methods of making and using thereof
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
US20030113350A1 (en) * 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US6720160B2 (en) * 2001-10-11 2004-04-13 Helica Biosystems, Inc. Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals
US7169903B2 (en) * 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
EP1474432A1 (en) * 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
FR2842210B1 (fr) * 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
EP2392582A3 (en) * 2003-04-25 2012-03-07 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
KR100596443B1 (ko) * 2004-04-27 2006-07-05 주식회사 하이닉스반도체 다수 뱅크 구조 디램을 위한 리프레시 제어회로 및 그 방법
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20060269998A1 (en) * 2005-04-15 2006-11-30 North Carolina State University Methods and compositions to modulate adhesion and stress tolerance in bacteria
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014237687A (ja) * 2007-08-31 2014-12-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
JP2017002080A (ja) * 2007-08-31 2017-01-05 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
JP2016525343A (ja) * 2013-05-31 2016-08-25 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2016532433A (ja) * 2013-05-31 2016-10-20 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
JP2019519509A (ja) * 2016-05-18 2019-07-11 ゲンマブ ビー．ブイ． 感染性疾患の治療における抗体およびその使用方法
JP2022105143A (ja) * 2016-05-18 2022-07-12 ゲンマブ ビー．ブイ． 感染性疾患の治療における抗体およびその使用方法

Also Published As

Publication number Publication date
AU2003298770A1 (en) 2004-06-23
AU2003298770A2 (en) 2004-06-23
EP1567868A2 (en) 2005-08-31
WO2004050846A8 (en) 2004-09-16
WO2004050846A2 (en) 2004-06-17
WO2004050846A3 (en) 2005-03-17
US20040247605A1 (en) 2004-12-09
CA2507711A1 (en) 2004-06-17
EP1567868A4 (en) 2008-02-06
AU2010200341A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
JP2006514636A (ja) 抗ブドウ球菌療法およびワクチンの標的としての壁テイコイン酸
EP2341929B1 (en) Compositions and methods related to bacterial emp proteins
US7777017B2 (en) Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
AU2009202762B2 (en) Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
CN113490686A (zh) 病原体结合蛋白
EP2464665B1 (en) Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation
JP2013053155A (ja) 黄色ブドウ球菌由来のポリペプチド及び使用方法
JP2010013454A (ja) グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体
Kahler et al. Structure-function relationships of the Neisserial EptA enzyme responsible for phosphoethanolamine decoration of lipid A: rationale for drug targeting
de Freitas et al. Promising targets for immunotherapeutic approaches against Acinetobacter baumannii
WO2014142117A1 (ja) 抗ブドウ球菌抗体、その製造方法並びにその使用
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
KR20150024315A (ko) 포도상구균 감염 예방용 백신 조성물
Żakowska et al. Bacillus anthracis infections–new possibilities of treatment
EA028912B1 (ru) Новый антибиотик, содержащий миметическое антитело, способы его приготовления и применения
KR20130036365A (ko) 감염 박테리아에서의 생물막 형성을 저감시키는 방법
US7544483B2 (en) Method for the production of protamine
Ebert et al. Development of a rat central venous catheter model for evaluation of vaccines to prevent Staphylococcus epidermidis and Staphylococcus aureus early biofilms
EP2889311B1 (en) Opsonic and protective monoclonal antibodies against gram-positive pathogens
WO2021079986A1 (ja) バクテリオファージ組成物
CN111565745B (zh) 细菌感染症用鸵鸟抗体
WO2021079536A1 (ja) バクテリオファージ組成物
Heilmann et al. Molecular basis of biofilm formation by Staphylococcus epidermidis
Bavro Lipid A: Rationale for Drug Targeting
Grousd Defining Staphylococcus aureus Virulence Factors in Bacterial Pneumonia and Influenza Super-Infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524